+1 Recommend
2 collections
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Diagnostic and prognostic potential of kallistatin in assessment of liver parenchyma changes in patients with non-alcoholic fatty liver disease and hypertension kallistatin in patients with NAFLD and hypertension

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Background and aim

          Non-alcoholic fatty liver disease (NAFLD) is closely linked to hypertension (HT). An important issue remains the search for non-invasive tests to NAFLD detection in the early stages of liver fibrosis. The objective of the study was to evaluate the diagnostic and prognostic value of kallistatin in assessing the liver fibrosis progression in NAFLD and HT patients.

          Patients and methods

          One hundred fifteen patients with NAFLD with and without HT were examined, the control group consisted of 20 relatively healthy volunteers. Plasma kallistatin level measurement, ultrasound steatometry and elastography were performed in all patients.


          Kallistatin level was 65.03 ng mL −1 (95% CI 61.38; 68.68), 83.42 ng mL −1 (95% CI 81.89; 84.94) and 111.70 ng mL −1 (95% CI 106.14; 113.22) in patients with NAFLD and HT, isolated NAFLD and control group, respectively. There were significant differences in the liver parenchyma condition between groups. Kallistatin levels strongly inversely correlated with the attenuation coefficient and the mean liver stiffness in NAFLD and HT (rs = −0.70) and in the isolated NAFLD patients (rs = −0.56; rs = −0.68, respectively). Kallistatin level was 71.82 ng mL −1 (95% CI 70.16; 79.51) and 58.62 ng mL −1 (95% CI 55.81; 64.45) in patients with HT stage I and HT stage II, respectively ( P < 0.001).


          Concomitant HT in NAFLD patients is associated with greater severity of fatty and fibrotic liver changes. The course of NAFLD is accompanied by decrease in kallistatin level. Increased degree of liver steatosis and fibrosis, inflammation activity, increased BMI and increased stage of HT lead to inhibition of kallistatin activity. Kallistatin may be considered as a biomarker for progression assessment of NAFLD with or without HT.

          Related collections

          Author and article information

          Akadémiai Kiadó (Budapest )
          20 December 2021
          08 September 2021
          : 13
          : 2
          : 152-159
          [1 ] Department of Internal Medicine No.1, Kharkiv National Medical University , Kharkiv, Ukraine
          [2 ] Government Institution “L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine” , Ukraine
          Author notes
          [* ]Corresponding author. E-mail: rozhdestvenska.anastasiia@ 123456gmail.com

          The study was conducted at the Department of Internal Medicine No. 1 of Kharkiv National Medical University that is located in The Government Institution “National Institute of Therapy named by L.T. Malaya of National Ukrainian Academy of Medical Science”.

          © 2021 The Author(s)

          Open Access. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium for non-commercial purposes, provided the original author and source are credited, a link to the CC License is provided, and changes – if any – are indicated.

          Page count
          Figures: 3, Tables: 2, Equations: 0, References: 29, Pages: 08

          Medicine,Immunology,Health & Social care,Microbiology & Virology,Infectious disease & Microbiology
          ultrasound steatometry,hypertension,NAFLD,non-alcoholic fatty liver disease,kallistatin,ultrasound elastography


          Comment on this article